Table 2.

Adverse reactions occurring at ≥3% than placebo in two placebo-controlled clinical trials in patients with HAE treated with ecallantide

Adverse reactions	Ecallantide (N=100), n (%)*	Placebo (N=100), n (%)
Headache	8 (8%)	6 (7%)
Nausea	5 (5%)	1 (1%)
Diarrhea	4 (4%)	3 (4%)
Pyrexia	4 (4%)	0
Injection site reaction	3 (3%)	1 (1%)
Nasopharyngitis	3 (3%)	0

Notes:

^*Patients experiencing the same adverse reaction more than one time were only counted once in that category. Adverse reactions of ecallantide compared to placebo from prescribing information package insert. Data from US FDA.²⁶

Abbreviation: HAE, hereditary angioedema.